Stacked bar graphs of the national number of GLP-1 RA claimants and market share of each GLP-1 RA by year for both formulary and non-formulary drug claims over time. The x-axis represents each year from 2016 to 2021 and the y-axis represents the number of GLP-1 RA claimants. Each section of each stacking bar represents a different GLP-1 RA. Overall, the number of GLP-1 RA claimants is increasing year over year, particularly the market share of Ozempic claimants.

Figure 1National Number of GLP-1 RA Claimants and Market Shares Across PT Formulary and Non-Formulary Drug Claims in Canada

GLP-1 = glucagon-like peptide-1; PT = provincial and territorial; RA = receptor agonist.

a Other GLP-1 RAs include Adlyxine, Bydureon, and Byetta.

From: Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists

Cover of Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists
Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists: Report [Internet].
Vannabouathong C, Crotty C, Le K, et al.; Authors.
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.